{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T14:44:58Z","timestamp":1770129898711,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"DOI":"10.7759\/cureus.102858","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T04:22:16Z","timestamp":1770092536000},"source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and Safety of Fixed-Dose Empagliflozin\/Linagliptin Combination in Type 2 Diabetes Mellitus: Real-World Evidence From Bangladesh"],"prefix":"10.7759","author":[{"given":"Indrajit","family":"Prasad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajit  K","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Saifuddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nusrat","family":"Sultana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mashfiqul","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masud-Un","family":"Nabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AKM  A","family":"Islam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moinul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Atiqur-Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad  I","family":"Mahbub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27030950","article-title":"Mechanistic insight into oxidative stress-triggered signaling pathways and type 2 diabetes","volume":"27","author":"Singh A","year":"2022","unstructured":"Singh A, Kukreti R, Saso L, Kukreti S. Mechanistic insight into oxidative stress-triggered signaling pathways and type 2 diabetes. Molecules. 2022, 27:950. 10.3390\/molecules27030950","journal-title":"Molecules"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2020.0254","article-title":"Diabetes fact sheets in Korea, 2020: an appraisal of current status","volume":"45","author":"Jung CH","year":"2021","unstructured":"Jung CH, Son JW, Kang S, et al.. Diabetes fact sheets in Korea, 2020: an appraisal of current status. Diabetes Metab J. 2021, 45:1-10. 10.4093\/dmj.2020.0254","journal-title":"Diabetes Metab J"},{"key":"ref3","unstructured":"Diabetes now affects one in 10 adults worldwide. (2021). Accessed. August 11, 2022: https:\/\/idf.org\/news\/diabetes-now-affects-one-in-10-adults-worldwide\/."},{"key":"ref4","article-title":"IDF Diabetes Atlas. 10th Edition","author":"Magliano DJ","year":"2021","unstructured":"Magliano DJ, Boyko EJ. IDF Diabetes Atlas. 10th Edition. International Diabetes Federation, Brussels; 2021."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12982-025-00813-1","article-title":"Prevalence and risk factors of diabetes among Bangladeshi adults: findings from a cross-sectional study","volume":"22","author":"Ahmed MF","year":"2025","unstructured":"Ahmed MF.  Prevalence and risk factors of diabetes among Bangladeshi adults: findings from a cross-sectional study. Discov Public Health. 2025, 22:450. 10.1186\/s12982-025-00813-1","journal-title":"Discov Public Health"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2337\/db09-9028","article-title":"Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"Defronzo RA","year":"2009","unstructured":"Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009, 58:773-95. 10.2337\/db09-9028","journal-title":"Diabetes"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4158\/CS-2017-0153","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2018 executive summary","volume":"24","author":"Garber AJ","year":"2018","unstructured":"Garber AJ, Abrahamson MJ, Barzilay JI, et al.. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2018 executive summary. Endocr Pract. 2018, 24:91-120. 10.4158\/CS-2017-0153","journal-title":"Endocr Pract"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies MJ","year":"2018","unstructured":"Davies MJ, D'Alessio DA, Fradkin J, et al.. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018, 41:2669-701. 10.2337\/dci18-0033","journal-title":"Diabetes Care"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2364","article-title":"Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin","volume":"38","author":"DeFronzo RA","year":"2015","unstructured":"DeFronzo RA, Lewin A, Patel S, Liu D, Kaste R, Woerle HJ, Broedl UC. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015, 38:384-93. 10.2337\/dc14-2364","journal-title":"Diabetes Care"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner C","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, et al.. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016, 375:323-34. 10.1056\/NEJMoa1515920","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017","volume":"17","author":"Einarson TR","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018, 17:83. 10.1186\/s12933-018-0728-6","journal-title":"Cardiovasc Diabetol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S010","article-title":"10. Cardiovascular disease and risk management: standards of medical care in diabetes-2022","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","unstructured":"American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2022. Diabetes Care. 2022, 45:S144-74. 10.2337\/dc22-S010","journal-title":"Diabetes Care"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock J","year":"2019","unstructured":"Rosenstock J, Perkovic V, Johansen OE, et al.. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019, 321:69-79. 10.1001\/jama.2018.18269","journal-title":"JAMA"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1027185","article-title":"Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin","volume":"31","author":"Aronson R","year":"2015","unstructured":"Aronson R. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin. Curr Med Res Opin. 2015, 31:901-11. 10.1185\/03007995.2015.1027185","journal-title":"Curr Med Res Opin"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4158\/EP14259.RA","article-title":"Fixed-dose combination therapy in type 2 diabetes mellitus","volume":"20","author":"Blonde L","year":"2014","unstructured":"Blonde L, San Juan ZT, Bolton P. Fixed-dose combination therapy in type 2 diabetes mellitus. Endocr Pract. 2014, 20:1322-32. 10.4158\/EP14259.RA","journal-title":"Endocr Pract"},{"key":"ref16","article-title":"A retrospective analysis of fixed combination of empagliflozin and linagliptin in addition to the existing treatment for its clinical effectiveness in adults with type 2 diabetes: a real-world clinical experience","volume":"69","author":"Gupta A","year":"2021","unstructured":"Gupta A, Malhotra P, Jamwal V, Khalse M. A retrospective analysis of fixed combination of empagliflozin and linagliptin in addition to the existing treatment for its clinical effectiveness in adults with type 2 diabetes: a real-world clinical experience. J Assoc Physicians India. 2021, 69:11-12.","journal-title":"J Assoc Physicians India"},{"key":"ref17","unstructured":"Glyxambi (empagliflozin and linagliptin) tablets. (2015). Accessed. August 2, 2023: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/206073Orig1s000TOC.cfm."},{"key":"ref18","unstructured":"Glyxambi. (2018). Accessed. August 3, 2023: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/glyxambi."},{"key":"ref19","unstructured":"Clinical practice guidelines for the management of diabetes mellitus in Bangladesh. (2019). Accessed. August 3, 2023: https:\/\/cghr-badas.org\/wp-content\/uploads\/2021\/11\/Diabetes_Care_BADAS_guideline2019.pdf."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2022.2107200","article-title":"Safety and effectiveness of empagliflozin and linagliptin fixed-dose combination therapy in Japanese patients with type 2 diabetes: final results of a one-year post-marketing surveillance study","volume":"22","author":"Inagaki N","year":"2023","unstructured":"Inagaki N, Nishimoto T, Nishiya Y, Nitta D. Safety and effectiveness of empagliflozin and linagliptin fixed-dose combination therapy in Japanese patients with type 2 diabetes: final results of a one-year post-marketing surveillance study. Expert Opin Drug Saf. 2023, 22:153-63. 10.1080\/14740338.2022.2107200","journal-title":"Expert Opin Drug Saf"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2018.01.011","article-title":"Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: a systematic review and meta-analysis","volume":"44","author":"Cho YK","year":"2018","unstructured":"Cho YK, Kang YM, Lee SE, et al.. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab. 2018, 44:393-401. 10.1016\/j.diabet.2018.01.011","journal-title":"Diabetes Metab"},{"key":"ref22","article-title":"Single-pill combination of empagliflozin and linagliptin in real-world Indian type 2 diabetes patients (GRID)","volume":"68","author":"Kovil R","year":"2020","unstructured":"Kovil R, Saboo B, Shah K, Padhye D, Chudasama D, Raj V, Shaikh N. Single-pill combination of empagliflozin and linagliptin in real-world Indian type 2 diabetes patients (GRID). J Assoc Physicians India. 2020, 68:53-5.","journal-title":"J Assoc Physicians India"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/446601-effectiveness-and-safety-of-fixed-dose-empagliflozinlinagliptin-combination-in-type-2-diabetes-mellitus-real-world-evidence-from-bangladesh","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T04:22:23Z","timestamp":1770092543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/446601-effectiveness-and-safety-of-fixed-dose-empagliflozinlinagliptin-combination-in-type-2-diabetes-mellitus-real-world-evidence-from-bangladesh"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.102858","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,2]]}}}